Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by wyndeweston Apr 19, 2017 8:52pm
204 Views
Post# 26140440

RE:RE:Boeheringer USA

RE:RE:Boeheringer USAFoof, the article at the end suggests Boeheringer made 17 Billion worldwide for a variety of drugs, activities, research etc. etc. The 17 Billion USD amounti s not describing sales for their fibrosis drug.  They don't put a $ amount on it.  Only that they are testing 600 patients with lung fibrosis of various types. The article to me, suggests Boehringer is a BIG worldwide player and as some have already said could probably swallow us up whole and in quick order if they wanted to....
Bullboard Posts